Keywords

Locations

Followed Suppliers

My Saved Searches

My Notes

Commodity Codes

Contract Vehicles

Followed Opportunities

My Briefcase

My Team

My documents

Followed Organizations

News Alerts

Agency documents

U.S. Department of Veterans Affairs (VA)

The Department of Veterans Affairs (VA), VISN 4, Network Contracting Office 4 (NCO 4), is seeking information and potential qualified sources for the purchase of 3 Bladder Scanner units. Patient care services requires one unit for 4W, 5W, and 6W. The purchase will include 3 bladder...

General Info

Contacts

Related commodity codes

Documents

Resume

MCDC

Contact Info

Size & Minority

Certifications

Product and Services

Past Experience

External Recognition

Location Served

Free

Follow the steps to access the new features. On average, completed pages of organizations are visited 30% more often.

Complete your Page

Biopharma, Biotechnology, Pharmaceutical, Cardiovascular, Metabolic Disorders,  Diseases, Inflammation, Immunology, Oncology, Immuno-Oncology, Antibody Drug Conjugates (ADCs), Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Antibody Research, Drug Discovery, Ebola Virus Antibody, Regeneron Genetics Center,  Antibodies Development,  FDA Approved Drugs, MERS  (MERS-CoV) Antibody, Monoclonal Antibody Discovery,  Drug Development, nCoV, Ebola Therapy,  Coronavirus (COVID-19), Coronavirus (COVID-19) - Vaccines and Therapeutics, SARS-CoV-2.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions.

REGENERON PHARMACEUTICALS INC

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA. 